Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Ascendis Pharma (ASND1N) Stock Price & Analysis

ASND1N Stock Chart & Stats

MX$4,165.55MX$0.00(0.00%)
At close:
Mex$4.3KMex$4.35KMex$4.4K4 Aug1 Sep
Day’s Range
MXN 4,165.55 - MXN 4,165.55
52-Week Range
MXN 3,460.21 - MXN 4,615.10
Previous Close
MXN 4,165.55
Volume
0
Average Volume (3M)
0
Market Cap
MXN 294.54B
Enterprise Value
MXN 17.81B
Total Cash (Recent Filing)
MXN 811.92M
Total Debt (Recent Filing)
MXN 449.89M
Price to Earnings (P/E)
18.5
Beta
-0.01
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
16.49
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Product Revenue Growth

Rapid growth across YORVIPATH, SKYTROFA and newly launched YUVIWEL shows that Ascendis is building a multi-product commercial base. Continued patient enrollment and management’s reiterated growth outlook could support durable revenue expansion as launches mature across additional markets.

Strong Cash Generation And Low Leverage

Positive operating and free cash flow, combined with substantial cash and no bank or convertible debt, gives Ascendis financial flexibility to fund launches, clinical development and potential expansion internally. This reduces near-term financing dependence while supporting continued investment in its pipeline.

Broadening Endocrine Pipeline

The TransCon platform supports multiple endocrine and rare-disease programs beyond the current commercial products. Positive achondroplasia data and planned annual regulatory filings create opportunities for label expansion and new launches, strengthening the company’s longer-term growth platform.

Bears Say

Profitability Remains Historically Inconsistent

The recent profit inflection has not yet been demonstrated across a full business cycle. Prior losses and deeply negative operating margins indicate that earnings and cash generation may remain sensitive to launch timing, investment levels and product performance as Ascendis scales.

Reported Profit Benefited From One-time Income

The priority review voucher sale materially increased reported operating and net profit, creating a gap between statutory and adjusted results. Because this income is non-recurring, underlying profitability is better represented by adjusted earnings and may be lower than headline results suggest.

Confirmatory Trial And Regulatory Risk

Dependence on confirmatory evidence means some product approvals and labels are not entirely insulated from future clinical outcomes. An unfavorable result could affect commercial durability, development priorities and the value of related investments, even as current launches perform well.

Ascendis Pharma News

ASND1N FAQ

What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was Mex$3460.21 and its highest was Mex$4615.10 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is Mex$294.54B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is in 9 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Aug 13, 2026. The company reported Mex$59.37 earnings per share for the quarter, beating the consensus estimate of Mex$31.405 by Mex$27.965.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is 16.49.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 62,376,846 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of Mex$59.37 in its last earnings report, beating expectations of Mex$31.405. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Hedge funds hold Ascendis Pharma shares: hedge funds decreased their holdings by 433.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology